Digital musculoskeletal (MSK) care triple-unicorn Hinge Health today announced the upcoming acquisition of Enso, the maker of an eponymous non-invasive electrical nerve stimulation device for pain relief.
Hinge Health did not disclose the terms of the deal or its impact on Enso employees, but a representative told MobiHealthNews that the purchase is set to close "within weeks."
The Enso device is...
Abbott announced today that it has updated NeuroSphere, its app-driven neuromodulation therapy platform, with remote programming capabilities that will allow patients to speak with and receive adjustments from their provider via a cellular or WiFi connection.
The NeuroSphere Virtual Clinic was recently approved by the FDA and is now available within the Abbott patient controller app for use with...
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
Fitbit and Belgium-based FibriCheck have extended their partnership to bring the latter’s atrial fibrillation detection app to four new countries in the EU: France, Germany, Italy and Spain. It was previously made available to Fitbit smartwatch users in the UK, Ireland, the Netherlands and Belgium back in September 2019.
“For more than a decade, Fitbit has helped millions of people around the...
The FDA has granted De Novo clearance to a prescription nerve stimulation device for the reduction of functional abdominal pain. The device is intended for use by adolescents and teens with irritable bowel syndrome in combination with other therapies.
Developed by Innovative Health Solutions, the IB-Stim devices is a single-use electrical nerve stimulator. When placed behind the patient’s ear, it...
Cala Health, a wearable neuromodulation therapy startup with Stanford University roots, has signed a licensing deal with Partners Healthcare affiliate Massachusetts General Hospital that will provide the former with a new nerve stimulation platform for chronic disease treatments.
According to the announcement, the technologies Cala is interested in were the product of MGH research on...
